Skip to main content
Physiatry '25 Main banner
Final Program


Final Program

229 - The Durability of Platelet Rich Plasma for Knee OA: A Comparison of Patient Acceptable Symptom State in Mild versus Advanced OA

Thursday, February 27, 2025
5:00 PM - 6:30 PM MST

    Presenting Author(s)

  • GH

    Gretchen L. Harknett, DO

    Resident Physician
    The Ohio State University
    Columbus, Ohio, United States

    • Co-Author(s)

  • Michael Baria, MD

    Associate Professor of Physical Medicine and Rehabilitation; Director of Sports Orthobiologics
    The Ohio State University
    Columbus, Ohio, United States

  • TB

    Tyler Barker, PhD

    Research and Science Director at Sports Medicine Research Institute
    The Ohio State University
    Columbus, Ohio, United States

Objectives: This study compares patient satisfaction and symptom management between early and advanced osteoarthritis (OA) patients receiving platelet-rich plasma (PRP) or micro-fragmented adipose tissue (MFAT) injections. The goal is to refine clinical recommendations and expectations for managing OA. 

Design: 58 patients with knee OA were screened and recruited from the sports medicine clinic. Patients received either PRP or MFAT injections. Patients were divided into early (n=20) versus advanced (n=29) OA based on Kellgren-Lawrence grade. Patients were followed for 12 months and outcomes were measured using KOOS PASS scores.  KOOS subscale differences were evaluated using Friedman ANOVA with post-hoc comparisons. Statistical significance was set at p < 0.05. 

Results:

In the early OA group, KOOS subscale scores (symptoms, pain, ADL, sport/recreation, quality of life) improved at 6 and 12 months compared to baseline, with no significant differences between these time points. In the advanced OA group, KOOS scores significantly increased from baseline to 6 months but showed a decline in symptoms, ADL, and sports/recreation (decreased in PASS count reported by 44%, 27.6%, and 31% respectively) by 12 months.  



KOOS PASS counts showed no significant differences between early and advanced OA groups at 6 months, but fewer advanced OA patients met PASS criteria for symptoms and sport/recreation at 12 months (37.9% and 55.1%, respectively; p-value 0.04).  In the early OA group, 70% and 85% met PASS criteria for the two KOOS subscale scores (p-value 0.04). Notably, more advanced OA patients who initially surpassed PASS criteria at 6 months fell below the threshold by 12 months compared to early OA patients. 


Conclusions: Early OA patients maintain stable PASS rates over one year, indicating sustained satisfaction. Advanced OA patients show declining PASS rates after 6 months, suggesting that clinicians can expect longer-lasting symptom management in mild OA patients, whereas advanced OA patients may require more frequent interventions.